Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp63878_8k.htm |
| EX-99.3 - EXIBIT 99.3 - Shire plc | dp63878_ex9903.htm |
| EX-99.4 - EXIBIT 99.4 - Shire plc | dp63878_ex9904.htm |
| EX-99.2 - EXIBIT 99.2 - Shire plc | dp63878_ex9902.htm |
Exhibit 99.1
| Press Release |  |
| www.shire.com |
Director/PDMR Shareholding
February 26, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that Sara Mathew, Non-Executive Director of the Company, acquired 1,000 American Depositary Shares (“ADSs”) today at an average price of $163.00 per ADS. The transaction took place on the NASDAQ Global Select Market. One ADS is equal to three Ordinary Shares of 5 pence each in the Company.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX